Table 4:
Performance Characteristics of PSA Screening Programs for Prostate Cancer
Abbreviations: ERSPC, European Randomized Study of Screening for Prostate Cancer; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
| Europe | North America | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERSPC, Belgium (45) | ERSPC, Netherlands (45) | ERSPC, Finland (45) | ERSPC, Italy (45) | ERSPC, Spain (45) | ERSPC, Sweden, Goteborg (45) | ERSPC, Switzerland (45) | ERSPC, France (73) | Norrkoping, Sweden (44) | Stockholm, Sweden (43) | Sweden, Goteborg (52) | USA, PLCO (40) | Canada, Quebec (46) | |
| Study participation, % | NR | 49 | 68 | 70 | 23 | 60 | 39 | 44 | 78 | 74 | 76 | NR | 24 |
| Screening compliance, % | 88.1 | 95 | 65 | 68 | 100 | 62 | 95 | 38 | 74 | NR | 59.7 | 85 | NR |
| Biopsy rates, % | 74.0 | 90 | 90 | 65 | 74 | 87 | 77 | 68 | 98 | NR | 93 | 40a | NR |
a
Biopsy participation was not by protocol.